The advantage of 3D conformal treatment of lumbar spine metastases in comparison to traditional PA or AP-PA techniques: restoring an intermediate niche of therapeutic sophistication
© Soyfer et al.; licensee BioMed Central Ltd. 2013
Received: 13 May 2012
Accepted: 6 February 2013
Published: 12 February 2013
To evaluate the effect of the 3D radiation field design on normal tissues compared with commonly used appositional fields in patients with lumbar spine metastases.
Methods and materials
Ten comparative treatment plans for radiation of lumbar spine metastases were compared for posterior and anterior- posterior fields with 3D plans.
The PTV coverage in all comparative plans was similar. V 15 of the bowel in 3D, AP-PA and PA plans was 6.7 Gy (SD 6.47), 39.8 Gy (SD 11.4) and 37.3 Gy (SD15.7), respectively (p < 0.0001). The mean dose to both kidneys was 9.6 Gy (SD 4.8), 4.1 Gy (SD 3.9) and 4.6 Gy (SD 4.4) for appropriate plans (p = 0.002). Maximal dose to the spinal cord was 30.6 Gy (SD 2.1), 33.1 Gy (SD 9.8) and 37.7 Gy (SD 2) for 3D, AP-PA and PA plans.
3D conformal treatment planning of lumbar vertebral metastases was significantly better in term of bowel and spinal cord exposure compared to AP-PA and PA techniques. The exposure of the kidneys in 3D plans, while greater than in the comparative plans, did not violate accepted dose-volume thresholds.
KeywordsSpine Metastases Radiation IMRT 3D
Bone metastases constitute a growing oncologic problem due to increasing life expectancy among cancer patients. The spine remains one of the most frequently involved sites for metastatic disease. In one study that evaluated 832 patients who died of their cancer, vertebral involvement was identified in 36% at autopsy.
One of the most commonly used approaches to treat painful bone metastases is external beam radiation therapy. The efficacy of radiation therapy in terms of pain alleviation ranges between 50–80%. Multiple publications including randomized studies, meta-analyses and guidelines have reflected on the best dose and fractionation needed to achieve durable palliation. The most popular regimens are 30 Gy in 10 fractions or 20 Gy in five fractions. A single 8 Gy fraction seems to be as effective as more protracted schedules[4–6].
Traditional technique for treating metastases of the spine is titrated to the location of the lesions. In the lumbar region, typical fields include a single posterior beam or anterior-posterior (AP-PA) portals, usually depending on the skin- target distance.
Over the past several decades the external beam irradiation armamentarium has expanded to include conformal three - dimensional (3D) radiotherapy, intensity modified radiation therapy (IMRT) and stereotactic approaches. Although these methods have been readily adopted by senior clinicians, it is difficult to identify peer-reviewed articles discussing the advantages of these new techniques above classical AP-PA or single posterior-anterior (PA) beam treatment of vertebral column metastases. Andic et al. analyzed three-dimensional (3D) data of conventional two- dimensional (2D) palliative spinal bone irradiation using different reference points and treatment plans with respect to the International Commission on Radiation Units and Measurements (ISRU) Report 50. They concluded that in palliative spinal bone irradiation, 2D conventional single posterior field radiotherapy did not comply with the ICRU Report 50 recommendations for PTV dose distribution, while AP-PA field plans did attain the intended dose ranges with a homogenous distribution and reasonable doses to the medulla spinalis, esophagus and intestines However, this relatively recently published study did not investigate the multiple field arrangements that might further improve the conformality of treatment Accordingly we were interested in assessing the relative benefits of several straightforward external beam approaches for treating spinal metastases with respect to target volume coverage and the potential influence of these respective beam arrangements on normal tissue (e.g., kidneys, small bowel, and spinal cord) tolerance.
Despite the fact that formal comparisons of 3-D techniques with even more traditional techniques (i.e., PA only, AP-PA) could have been carried out years ago, the absence of such comparisons in the literature prompted us to rigorously evaluate this matter. The issue has assumed greater importance because today, patients with bone metastases live longer and therefore the opportunity to manifest delayed complications has become greater. Moreover, hypofractionated regimes are often considered in an era where not only stereotactic body radiation therapy but also intensity modulated radiation therapy is practiced. As such, large doses are given to associated organs per fraction with heightened concerns for late toxicity.
Methods and materials
Ten comparative plans were evaluated from randomly chosen patients with lumbar spine metastases who were treated from 2007 to 2010. Ages ranged from 44–86 (median 74). There were 4 women and six men. The distribution of primary tumors included three patients with lung cancer, three men with prostate cancer, two women with breast cancer, one patient with colorectal cancer as well as one individual with gastric cancer.
Every patient underwent CT simulation on a Big Bore CT unit (Philips, Eindhoven, Netherlands) with 3 mm slices. All patients were placed in the supine position with arms above the head. The gross tumor volume (GTV) was delineated in accordance with the visible lesions on imaging studies. A normal appearing vertebral body above and below the radiographic abnormality was encompassed to generate the clinical treatment volume (CTV). The planning treatment volume (PTV) included an additional 5–10 mm around the CTV in deference to multi-leaf collimator constrants and daily position inaccuracy. The upper and lower margins of PTV were limited at the intervertebral disc spaces. Critical organs (kidneys, spinal cord and bowel) were delineated separately. Bowel loops were easily identified on each slide rather than delineating the whole abdominal cavity. Patients were immobilized using a standard laser system. Total doses of 30 Gy in 3 Gy fractions were prescribed to the point located at the center of the PTV that is in accordance with the ICRU 50. The energy of X rays was 6 or 18 MV or their combinations depending on the depth of the isocenter.
A comparison of group means of all the parameters was performed using a one-way analysis of variance. The Multiple comparison adjustment method “GT2” by Hochberg was employed to determine significant differences between pairs of groups. SAS for Windows version 9.2 was used for the analysis.
Irradiation has constituted a traditional therapeutic option for palliation of lumbar metastases. Historically, extensive research has explored optimal dose-fractionation relationships for his modality. However, despite the modern revolution in treatment planning there is limited information on sophisticated field configuration for the irradiation of the lumbar spine. Our results indicate that similar PTV coverage can be achieved in the three comparative plans selected but that the optimal dose distribution is associated with the 3-D plan which was developed.
Approximately 70% of cancer patients have metastatic disease at death. The spine is involved in up to 40% of those patients. Spinal cord compression may develop in 5% to 10% of cancer patients and up to 40% of patients with preexisting nonspinal bone metastasis (>25,000 cases/y). Given the increasing survival times of patients with cancer, greater numbers of patients are likely to develop this complication. Such lesions are most frequently encountered in the management of patients diagnosed with cancers of the breast and prostate. Patients with bone metastases that arise from the latter two primary malignancies can enjoy median survival times that are measured in years while mean survival times as low as 6 months from bronchogenic carcinoma are seen in contemporary series.
External beam irradiation constitutes a time-honored intervention for the treatment of bone metastases; especially those situated in the spine. Controversies surrounding dose fractionation schedules for bone metastases have preoccupied radiation oncologists for years. Not only retrospective series but also numerous randomized controlled clinical trials have stated that similar pain relief outcomes are achievable with short and long course of radiotherapy. Prescriptions for radiation treatment, however, require more specification than the delineation of dosage, beam energy and notation of total and fractional dose.
Despite the abundance of information regarding dose-fractionation regimens for spinal metastases, limited data exist regarding the comparison of various techniques in the treatment of the spine. Although sophisticated approaches such as stereotactic body irradiation for spinal metastases have been readily adopted by many institutions such technologies are not available to all users around the world. Therefore, a formal assessment must be made of more accessible technologies.
Radiation oncologists have always concerned themselves with both components that comprise the “therapeutic index”. Our data underscore the value of the 3D conformal approach for spinal metastases as a palliative tool. When treating the lumbar spine; however, several organs are at a risk for expressing radiation-related damage. In term of anticipated acute small bowel toxicity Baglan et al. showed that irradiation of more than 15 Gy to at least 150 cm3 is associated with an incidence of grade 3 acute small bowel toxicity approximating 30% using the Common Toxicity Criteria scale[15, 16]. The mean radiation dose at which diarrhea grade 2–3 occurred was 27 Gy according toGunnlaugsson A et al. . Comprehensive review of the radiation dose- volume effects in small bowel was published by Kavanagh et al. in 2010. According to those authors, following doses on the order of 50 Gy, late small-bowel obstruction or perforation rates of 2% to 9% were observed after partial organ irradiation. A dose of 25 Gy in five fractions of preoperative radiation therapy is associated with the same rate of late toxicity. It was also underscored in the review that small bowel obstruction occurred in 30% when fields were extended to the level of L1 or L2 versus 9% with pelvic- only therapeutic strategies. Reports on the probability of the late small bowel damage could not be identified in correlation with the radiation dose- volume function. Notwithstanding, we reasoned that maximum effort should be invested to spare as much small bowel from the radiation field as possible. As a surrogate, we reported in our study the mean volume of the bowel irradiated and V15.
It must be acknowledged that one of the possible disadvantages in conformal 3D radiation techniques which employ a paired set of oblique wedged fields is the deposition of higher doses within the kidneys. The risks of radiation damage to the kidneys were comprehensively summarized by Dawson et al. The dose associated with a 5% risk for toxicity at 5 years was 18–23 Gy regardless of the fractionation scheme used. It was within the context of these criteria that we carried out a comparative assessment of potential renal damage from radiation treatment.
Although the beam arrangements evaluated herein were not associated with optimal renal sparing, the dose volume histograms which paid attention to the kidney suggest that such treatments can be delivered without inducing nephropathy. Moreover, vis-à-vis other adjacent critical organs (e.g., bowel, spinal cord) the conformal approach offered significant improvement. As indicated, none of the 3 approaches evaluated was associated with advantages in terms of target coverage.
A recently published trial by the RTOG (97–14) assessed quality of life endpoints among patients suffering from bone metastases[20, 21]. As predicted, radiation therapy was highly effective in reducing bone pain. The framers of the protocol allowed physicians to treat patients who presented with spinal metastases via AP-PA or posterior-only portals. Despite the availability of conformal approaches during the recruitment period of the protocol, no allowance was made for selecting such an option. While this decision may have successfully isolated the dose fractionation question (i.e., by eliminating the variability in radiation treatment approaches) it is possible that patients enrolled in the study were impacted upon from a QOL perspective due to the use of non-optimized portal arrangements.
The RTOG is about to open the phase III component of protocol l 06–31 which will randomize patients diagnosed with bone metastases between SBRT and other forms of external beam radiation therapy. While the protocol does stipulate that for those randomized to the conventional treatment arm “field arrangements to treat the target lesion may be chosen at the discretion of the treating radiation oncologist” the study goes on to provide detailed suggestions for treating the spine via 2-field approaches (AP-PA for thoraco-lumbar spine; lateral beams for cervical spine) with only cursory mention of the possibility of using oblique beams.
The absence of rigorous comparisons of portal selection is also evident in reference textbooks as well as the recent evidence-based ASTRO guidelines on palliative radiotherapy for bone metastases which provide extensive information on dose volume relationships but fail to bring up the matter of optimal field arrangements when conventional irradiation is employed. The reality is that 3D conformal RT is already the standard procedure for irradiation in many institutions worldwide. However, even in the most recently published update of the International Consensus on palliative RT endpoints for future clinical trials in bone metastases opinion was split between prescribing the dose to the mid-vertebral body or anterior vertebral body for a single direct field and the guidelines for conformal radiotherapy and stereotactic radiotherapy were subsumed under the rubric of “future research areas”. Ironically, the same guidelines devote extensive space towards consideration of SBRT techniques despite the fact that the use of the latter is not yet justifiable with level 1 evidence. Since the authors of these guidelines do not yet consider SBRT to be a standard of care, we believe that data must still be collected regarding the merits of modern as well as conventional beam arrangements.
It is troubling to reflect on the current reality of extremes. Today’s clinician seems to be left with polarized options for treating bone metastases of the spine. Specifically, physicians can avail themselves of the most modern variants of SBRT; however, there are certainly many palliative cases which do not require this level of sophistication. Conversely, alternative options that are documented in the literature include the most rudimentary radiation techniques (i.e. Posterior beams or combination of AP and PA fields). The rationale for presenting our results is to re-orient the clinician to an intermediate level of sophistication in the palliative approach to this entity.
In summary, 3D conformal radiation treatment of lumbar vertebral metastases was significantly better in term of bowel and spinal cord exposure when compared to AP-PA and PA techniques. The routine deployment of stereotactic body radiation therapy and intensity modulated radiation therapy for management of bone metastases may represent an unnecessary expenditure of resources. Clinicians should therefore continue to avail themselves of 3D conformal approaches as dictated by the complexity of the clinical case being evaluated.
Anterior- posterior- posterior-anterior
Intensity modulated radiation therapy
the International Commission on Radiation Units and Measurements
Gross tumor volume
Clinical target volume
Planning target volume.
- Perez CA, Brady LW, Roti Roti JL, et al.: Overview. In Principles and practice of radiation oncology. 3rd edition. Edited by: Perez CA, Brady LW. Philadelphia, Pa: Lippincott-Raven; 1997.
- Wong DA, Fornasier VL, MacNab I: Spinal metastases: the obvious, the occult, and the impostors. Spine (Phila Pa 1976) 1990, 15: 1-4. 10.1097/00007632-199001000-00001View Article
- Chow E, Harris K, Fan G, et al.: Palliative radiotherapy trials for bone metastases: A systematic review. J Clin Oncol 2007, 25: 1423-1436. 10.1200/JCO.2006.09.5281View ArticlePubMed
- Fairchild A, Barnes E, Ghosh S, et al.: International patterns of practice in palliative radiotherapy for painful bone metastases: Evidence-based practice? Int J Radiat Oncol Biol Phys 2009, 75: 1281-1628.View Article
- Wu J, Wong R, Lloyd N, et al.: Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases—An evidence-based practice guideline. BMC Cancer 2004, 4: 71-78. 10.1186/1471-2407-4-71View ArticlePubMedPubMed Central
- Lutz S, Berk L, Chang E, Chow E, et al.: Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011,79(4):965-976. Mar 15 10.1016/j.ijrobp.2010.11.026View ArticlePubMed
- Corn WB, Glatstein E: The most important question. Int J Radiat Oncol Biol Phys 2009,74(4):985-986. 10.1016/j.ijrobp.2009.03.044View ArticlePubMed
- Andic F, Baz Cifci S, Ors Y, Niang U, Dirier A, Adli M: A dosimetric comparison of different treatment plans of palliative spinal bone irradiation: analysis of dose coverage with respect to ICRU 50 Report. J Exp Clin Cancer 2009, 28: 2. 10.1186/1756-9966-28-2View Article
- Hochberg GT2 test. http://srmo.sagepub.com/view/the-sage-dictionary-of-statistics/n248.xml
- Schmidt MH, Klimo PJ, Vrionis FD: Metastatic spinal cord compression. J Nati Compr Canc Netw 2005,3(5):711-719.
- Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12: 6243. 10.1158/1078-0432.CCR-06-0931View Article
- Gaze MN, Kelly CG, Kerr GR, et al.: Pain relief and quality of life following radiotherapy for bone metastases: A randomized trial of two fractionation schedules. Radiother Oncol 1997, 45: 109-116. 10.1016/S0167-8140(97)00101-1View ArticlePubMed
- Halperin E, Perez C, Brady WL: Principles and Practice of Radiation Oncology. Fifth edition. Philadelphia: Lippincott Williams & Wiklins; 2008:p 773.
- Sahgal A, Larson D, Chang EL: Stereotactic body radiosurgery for spinal metastases: A critical review. IJORBP 2008, 71: 652-665.
- Baglan K, Frazier R, Yan D, et al.: The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU- based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002,52(1):176-183. 10.1016/S0360-3016(01)01820-XView ArticlePubMed
- Trotti A, Byhardt R, Stetz J, et al.: Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment (Impact on radiotherapy). Int J Radiat Oncol Biol Phys 2000, 47: 13-47. 10.1016/S0360-3016(99)00559-3View ArticlePubMed
- Gunnlaugsson A, Kjellén E, Nilsson P, et al.: Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. Acta Oncol 2007, 46: 937-944. 10.1080/02841860701317873View ArticlePubMed
- Kavanagh B, Pan C, Dawson L, et al.: Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 2010,76(3):101-107. 10.1016/j.ijrobp.2009.05.071View Article
- Dawson L, Kavanagh B, Paulino A, et al.: Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys 2010, 76: 108-115. 10.1016/j.ijrobp.2009.02.089View Article
- Randomized trial of palliative radiation therapy for osseous metastases: a study of palliation of symptoms and quality of life for osseous metastases: a study of palliation of symptoms and quality of life (RTOG 9714). http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=9714
- Hartsell WF, Desilvio M, Bruner DW, et al.: Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97–14. J Palliat Med 2008,11(5):723-728. 10.1089/jpm.2007.0259View ArticlePubMed
- Radiation therapy oncology group rtog0631. Phase ii/iii study of image-guided radiosurgery/sbrt for localized spine metastasis. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0631
- Chow E, Hoskin P, Mitera G, et al.: Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys 2012,82(5):1730-1737. 10.1016/j.ijrobp.2011.02.008View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.